Trivalent car T-cells overcome interpatient antigenic variability in glioblastoma
Neuro-Oncology Oct 05, 2017
Bielamowicz K, et al. - This study addressed whether targeting 3 antigens using a single Chimeric Antigen Receptor (CAR) T-cell product can overcome interpatient antigenic variability in Glioblastoma (GBM). As per observations, universal CAR T-cells have the potential for overcoming antigenic heterogeneity in GBM and can lead to improved treatment outcomes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
